Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series

BACKGROUND: Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be an effective treatment for NRG1 fusion‐driven tumors. PATIENTS AND METHODS: This report summarizes pertinent details, includ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Cadranel, Jacques, Liu, Stephen V., Duruisseaux, Michaël, Branden, Eva, Goto, Yasushi, Weinberg, Benjamin A., Heining, Christoph, Schlenk, Richard F., Cheema, Parneet, Jones, Martin R., Drilon, Alexander, Trombetta, Domenico, Muscarella, Lucia Anna, Tolba, Khaled, Gounant, Valerie, Cseh, Agnieszka, Solca, Flavio, Laskin, Janessa J., Renouf, Daniel J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Precision Medicine Clinic: Molecular Tumor Board
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794194/
https://ncbi.nlm.nih.gov/pubmed/32852072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0379
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados